Free tool
FAERS Monitor: Premarin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021417 or its brand name (Premarin, Estrogens, Conjugated). Reports on generic versions are filed under their own applications.
Reports
59,171
Serious
41,980
71% of reports
Hospitalization
9,522
Death reported
1,854
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- breast cancer9,643
- breast cancer female8,869
- drug ineffective3,442
- nausea2,413
- headache2,369
- pain2,304
- fatigue2,284
- off label use2,231
- dizziness1,686
- breast cancer metastatic1,682
- dyspnoea1,661
- malaise1,616
- diarrhoea1,564
- arthralgia1,497
- anxiety1,447
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4,156 |
| 2005 | 3,642 |
| 2006 | 3,215 |
| 2007 | 1,686 |
| 2008 | 3,634 |
| 2009 | 5,174 |
| 2010 | 9,123 |
| 2011 | 2,685 |
| 2012 | 2,581 |
| 2013 | 2,149 |
| 2014 | 2,043 |
| 2015 | 2,431 |
| 2016 | 2,530 |
| 2017 | 1,975 |
| 2018 | 1,787 |
| 2019 | 2,160 |
| 2020 | 2,285 |
| 2021 | 1,520 |
| 2022 | 1,402 |
| 2023 | 1,079 |
| 2024 | 856 |
| 2025 | 641 |
| 2026 | 412 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,994,988 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 8,869 | 176.1 | 171.9 | 1,033,158 |
| breast cancer metastaticSignal | 1,682 | 65.9 | 62.6 | 90,607 |
| breast cancerSignal | 9,643 | 40.9 | 40.1 | 338,030 |
| anxiety | 1,447 | 1.8 | 1.7 | 530 |
| headache | 2,369 | 1.3 | 1.3 | 214 |
| pain | 2,304 | 1.3 | 1.3 | 198 |
| malaise | 1,616 | 1.3 | 1.2 | 121 |
| arthralgia | 1,497 | 1.3 | 1.2 | 93 |
| dizziness | 1,686 | 1.2 | 1.1 | 58 |
| nausea | 2,413 | 1.1 | 1.0 | 16 |
| dyspnoea | 1,661 | 1.0 | 1.0 | 3 |
| fatigue | 2,284 | 1.0 | 1.0 | 4 |
| drug ineffective | 3,442 | 0.9 | 0.9 | 20 |
| off label use | 2,231 | 0.9 | 0.9 | 23 |
| diarrhoea | 1,564 | 0.9 | 0.8 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.